The fact that patients with t(11;14) and patients with higher BCL2 expression appear to have a more favourable benefit–risk profile than patients without t(11;14) and with lower BCL2 expression suggests that a biomarker-driven approach may be appropriate for the administration of venetoclax in multiple myeloma patients [66]. The gene discussed is BCL2; the disease is plasma cell myeloma.